International Cancer Detection and Prevention Center, Chiba City, Mihama-ku Takasu 3-21-1, Japan.
Cancer Med. 2018 Mar;7(3):549-556. doi: 10.1002/cam4.1275. Epub 2018 Feb 21.
Diagnosis using a specific tumor marker is difficult because the sensitivity of this detection method is under 20%. Herein, a tumor marker combination assay, combining growth-related tumor marker and associated tumor marker (Cancer, 73(7), 1994), was employed. This double-blind tumor marker combination assay (TMCA) showed 87.5% sensitivity as the results, but a low specificity, ranging from 30 to 76%. To overcome this low specificity, we exploited complex markers, a multivariate analysis and serum fractionation by biochemical biopsy. Thus, in this study, a combination of new techniques was used to re-evaluate these serum samples. Three serum panels, containing 90, 120, and 97 samples were obtained from the Mayo Clinic. The final results showed 80-90% sensitivity, 84-85% specificity, and 83-88% accuracy. We demonstrated a notable tumor marker combination assay with high accuracy. This TMCA should be applicable for primary cancer detection and recurrence prevention.
由于这种检测方法的灵敏度低于 20%，因此使用特定肿瘤标志物进行诊断较为困难。在此，采用了一种肿瘤标志物联合检测方法（Cancer，73（7），1994），将生长相关肿瘤标志物和相关肿瘤标志物相结合。该双盲肿瘤标志物联合检测方法（TMCA）的检测结果显示出 87.5%的灵敏度，但特异性较低，范围在 30%至 76%之间。为了克服这种低特异性，我们利用了复杂的标志物、多变量分析和生化活检的血清分离。因此，在这项研究中，我们使用了一系列新技术来重新评估这些血清样本。从梅奥诊所获得了包含 90、120 和 97 个样本的三个血清组。最终结果显示，该方法的灵敏度为 80-90%，特异性为 84-85%，准确性为 83-88%。我们展示了一种具有高准确性的显著肿瘤标志物联合检测方法。这种 TMCA 应该适用于原发性癌症的检测和复发预防。
